415 related articles for article (PubMed ID: 30058899)
1. Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life.
Oriot P; Jérémie W; Buysschaert M
Expert Rev Endocrinol Metab; 2018 May; 13(3):167-171. PubMed ID: 30058899
[TBL] [Abstract][Full Text] [Related]
2. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis.
Nakanishi S; Iwamoto M; Kamei S; Hirukawa H; Shimoda M; Tatsumi F; Kohara K; Obata A; Kimura T; Kinoshita T; Irie S; Sanada J; Fushimi Y; Nishioka M; Mizoguchi A; Kameyama M; Mune T; Kaku K; Kaneto H
Intern Med; 2018; 57(10):1381-1389. PubMed ID: 29760318
[TBL] [Abstract][Full Text] [Related]
4. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.
Gupta S; Wang H; Skolnik N; Tong L; Liebert RM; Lee LK; Stella P; Cali A; Preblick R
Adv Ther; 2018 Jan; 35(1):43-55. PubMed ID: 29313285
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis.
Díez-Fernández A; Cavero-Redondo I; Moreno-Fernández J; Pozuelo-Carrascosa DP; Garrido-Miguel M; Martínez-Vizcaíno V
Acta Diabetol; 2019 Mar; 56(3):355-364. PubMed ID: 30506484
[TBL] [Abstract][Full Text] [Related]
6. Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study.
Escalada J; Bonnet F; Wu J; Bonnemaire M; Gupta S; Cambron-Mellott JM; Nicholls C; Müller-Wieland D
Adv Ther; 2020 Sep; 37(9):3863-3877. PubMed ID: 32681460
[TBL] [Abstract][Full Text] [Related]
7. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1).
Matsuhisa M; Koyama M; Cheng X; Takahashi Y; Riddle MC; Bolli GB; Hirose T;
Diabetes Obes Metab; 2016 Apr; 18(4):375-83. PubMed ID: 26662964
[TBL] [Abstract][Full Text] [Related]
8. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.
Yale JF; Aroda VR; Charbonnel B; Sinclair AJ; Trescoli C; Cahn A; Bigot G; Merino-Trigo A; Brulle-Wohlhueter C; Bolli GB; Ritzel R
Diabetes Metab; 2020 Apr; 46(2):110-118. PubMed ID: 30366067
[TBL] [Abstract][Full Text] [Related]
9. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension.
Yki-Järvinen H; Bergenstal RM; Bolli GB; Ziemen M; Wardecki M; Muehlen-Bartmer I; Maroccia M; Riddle MC
Diabetes Obes Metab; 2015 Dec; 17(12):1142-9. PubMed ID: 26172084
[TBL] [Abstract][Full Text] [Related]
10. Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study.
Abitbol A; Brown RE; Jiandani D; Sauriol L; Aronson R
Can J Diabetes; 2019 Oct; 43(7):504-509.e1. PubMed ID: 31256905
[TBL] [Abstract][Full Text] [Related]
11. Real-world Safety and Effectiveness of Insulin Glargine 300 U/mL in Participants with Type 2 Diabetes Mellitus During the Period of Ramadan in Four Countries (Egypt, Jordan, Lebanon, and Turkey): A Prospective Observational Study.
Hassanein M; Shaltout I; Malek R; Assaad Khalil S; Ballout H; Annabi F; Shereen M
Curr Diabetes Rev; 2024; 20(5):e110823219694. PubMed ID: 37581325
[TBL] [Abstract][Full Text] [Related]
12. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).
Terauchi Y; Koyama M; Cheng X; Takahashi Y; Riddle MC; Bolli GB; Hirose T
Diabetes Obes Metab; 2016 Apr; 18(4):366-74. PubMed ID: 26662838
[TBL] [Abstract][Full Text] [Related]
13. Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
Roussel R; d'Emden MC; Fisher M; Ampudia-Blasco FJ; Stella P; Bizet F; Cali AMG; Wysham CH
Diabetes Obes Metab; 2018 Feb; 20(2):448-452. PubMed ID: 28736942
[TBL] [Abstract][Full Text] [Related]
14. Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).
Home PD; Bergenstal RM; Bolli GB; Ziemen M; Rojeski M; Espinasse M; Riddle MC
Diabetes Obes Metab; 2018 Jan; 20(1):121-128. PubMed ID: 28661585
[TBL] [Abstract][Full Text] [Related]
15. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
Wolnik B; Wiza D; Szczepanik T; Syta A; Klupa T
J Diabetes Res; 2020; 2020():8751348. PubMed ID: 32337298
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures.
Lingvay I; Chao J; Dalal MR; Meneghini LF
Diabetes Technol Ther; 2017 May; 19(5):315-322. PubMed ID: 28467113
[TBL] [Abstract][Full Text] [Related]
17. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
Home PD; Bergenstal RM; Bolli GB; Ziemen M; Rojeski M; Espinasse M; Riddle MC
Diabetes Care; 2015 Dec; 38(12):2217-25. PubMed ID: 26084341
[TBL] [Abstract][Full Text] [Related]
18. INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETES.
Munshi MN; Gill J; Chao J; Nikonova EV; Patel M
Endocr Pract; 2018 Feb; 24(2):143-149. PubMed ID: 29106816
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
Home PD; Lam RLH; Carofano WL; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rosenstock J; Hollander PA; Gallwitz B
Diabetes Obes Metab; 2018 Sep; 20(9):2220-2228. PubMed ID: 29766635
[TBL] [Abstract][Full Text] [Related]
20. Comparison of insulin glargine 300 U/mL versus glargine 100 U/mL on glycemic control and hypoglycemic events in East Asian patients with type 2 diabetes: A Patient-level meta-analysis of phase 3 studies.
Ji L; Bi Y; Ye S; Huang Y; Zhang X; Shang S; Cui N; Yin H; Zhang M
Diabetes Res Clin Pract; 2021 Jun; 176():108848. PubMed ID: 33945841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
